ES2543050T3 - Inhibidores de serina/treonina quinasa - Google Patents
Inhibidores de serina/treonina quinasa Download PDFInfo
- Publication number
- ES2543050T3 ES2543050T3 ES12709429.0T ES12709429T ES2543050T3 ES 2543050 T3 ES2543050 T3 ES 2543050T3 ES 12709429 T ES12709429 T ES 12709429T ES 2543050 T3 ES2543050 T3 ES 2543050T3
- Authority
- ES
- Spain
- Prior art keywords
- dihydro
- phenyl
- pyrido
- amide
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CI1=C(NC2CCOCC2)N=C(CN(CC2)C(N[C@]([C@]3OCCNC3)c3ccc(*)c(F)c3)=O)C2=C1 Chemical compound CI1=C(NC2CCOCC2)N=C(CN(CC2)C(N[C@]([C@]3OCCNC3)c3ccc(*)c(F)c3)=O)C2=C1 0.000 description 2
- WXJPMLSWTPVESE-GPCIUJRVSA-N CN/C=C(/CCN(C1)C(CCC(CN(C2)N)[C@@H]2C(CC=C2)C=C2F)=O)\C1=N/CNc(ccc(F)c1)c1N Chemical compound CN/C=C(/CCN(C1)C(CCC(CN(C2)N)[C@@H]2C(CC=C2)C=C2F)=O)\C1=N/CNc(ccc(F)c1)c1N WXJPMLSWTPVESE-GPCIUJRVSA-N 0.000 description 1
- KCQCABHMPBMAAV-UHFFFAOYSA-O N=CC(C[NH2+]C1)C1c(cc1)cc(F)c1Cl Chemical compound N=CC(C[NH2+]C1)C1c(cc1)cc(F)c1Cl KCQCABHMPBMAAV-UHFFFAOYSA-O 0.000 description 1
- RQONZUTXVNYYBC-UHFFFAOYSA-M O=C(C(CC1)Cc2c1cnc(NC1CCOCC1)n2)[N-]C(CC1NCCC1)c(cc1F)ccc1Cl Chemical compound O=C(C(CC1)Cc2c1cnc(NC1CCOCC1)n2)[N-]C(CC1NCCC1)c(cc1F)ccc1Cl RQONZUTXVNYYBC-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161447587P | 2011-02-28 | 2011-02-28 | |
| US201161447587P | 2011-02-28 | ||
| PCT/US2012/027009 WO2012118850A1 (en) | 2011-02-28 | 2012-02-28 | Serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2543050T3 true ES2543050T3 (es) | 2015-08-14 |
Family
ID=45852719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12709429.0T Active ES2543050T3 (es) | 2011-02-28 | 2012-02-28 | Inhibidores de serina/treonina quinasa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9133187B2 (enExample) |
| EP (1) | EP2681215B1 (enExample) |
| JP (1) | JP6085866B2 (enExample) |
| KR (1) | KR101961500B1 (enExample) |
| CN (1) | CN103635472B (enExample) |
| BR (1) | BR112013021896A2 (enExample) |
| CA (1) | CA2828478C (enExample) |
| ES (1) | ES2543050T3 (enExample) |
| MX (1) | MX339873B (enExample) |
| RU (1) | RU2013143839A (enExample) |
| WO (1) | WO2012118850A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| AP2013007331A0 (en) | 2011-06-24 | 2013-12-31 | Amgen Inc | TRPM8 antagonists and their use in treatments |
| EP2723718A1 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| ES2552989T3 (es) * | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| RU2632659C2 (ru) * | 2011-12-27 | 2017-10-09 | Байо-Фарм Солюшнс Ко., Лтд. | Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии |
| PE20150666A1 (es) | 2012-03-01 | 2015-05-06 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| CA2882750A1 (en) | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
| CA2882410A1 (en) * | 2012-09-19 | 2014-03-27 | Novartis Ag | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
| EP2909206A1 (en) | 2012-10-16 | 2015-08-26 | F. Hoffmann-La Roche AG | Serine/threonine kinase inhibitors |
| JPWO2015012328A1 (ja) * | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EA031243B1 (ru) | 2013-12-06 | 2018-12-28 | Дженентек, Инк. | Ингибиторы серин/треонинкиназ |
| MX375902B (es) | 2013-12-30 | 2025-03-07 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| KR102379517B1 (ko) * | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| ES2863873T3 (es) * | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| JP6986565B2 (ja) | 2017-09-29 | 2021-12-22 | 田辺三菱製薬株式会社 | 光学活性ピロリジン化合物及びその製造方法 |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| KR20210145773A (ko) | 2019-03-28 | 2021-12-02 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 티에노헤테로고리형 유도체, 이의 제조 방법 및 이의 의약적 용도 |
| WO2020200069A1 (zh) | 2019-03-29 | 2020-10-08 | 江苏恒瑞医药股份有限公司 | 吡咯并杂环类衍生物、其制备方法及其在医药上的应用 |
| EP3978498A1 (en) | 2019-05-24 | 2022-04-06 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines |
| CN113874374B (zh) * | 2019-05-24 | 2024-12-27 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN111170929A (zh) * | 2019-12-12 | 2020-05-19 | 北京达因高科儿童药物研究院有限公司 | 一种由末端烯烃制备β-氨基醇的方法 |
| EP4217356B1 (en) | 2020-09-25 | 2025-05-14 | JANSSEN Pharmaceutica NV | Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitors |
| US20230331731A1 (en) | 2020-09-29 | 2023-10-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of pyrrolo heterocyclic derivative and preparation method therefor |
| CN115040522B (zh) * | 2022-06-30 | 2024-02-06 | 牡丹江医学院 | 一种用于治疗肺癌的药物及其制备方法 |
| KR20250091232A (ko) * | 2022-10-25 | 2025-06-20 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 피페리디노피리미딘계 유도체, 이의 제조 방법 및 이의 의학적 응용 |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
| TW202535869A (zh) * | 2023-10-23 | 2025-09-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種含有噻唑基的哌啶并嘧啶類衍生物、其製備方法及其醫藥上的應用 |
| WO2025223512A1 (zh) * | 2024-04-24 | 2025-10-30 | 江苏恒瑞医药股份有限公司 | 一种二氢吡啶并嘧啶衍生物的可药用盐、结晶形式及用途 |
| WO2026067627A1 (zh) * | 2024-09-26 | 2026-04-02 | 江苏恒瑞医药股份有限公司 | 一种降解剂及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| PT672042E (pt) | 1993-10-01 | 2006-08-31 | Novartis Ag | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CA2274093C (en) | 1996-12-05 | 2006-11-07 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| YU63802A (sh) | 2000-02-25 | 2005-06-10 | F. Hoffmann-La Roche Ag. | Modulatori adenozinskih receptora |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MXPA04011470A (es) | 2002-05-21 | 2005-02-14 | Amgen Inc | Compuestos heterociclicos sustituidos y metodos de uso. |
| WO2004007468A1 (en) * | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| JP2007532669A (ja) | 2004-04-13 | 2007-11-15 | イカジェン インコーポレイテッド | カリウムイオンチャネル調節剤としての多環式ピリミジン |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| CA2578122A1 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| WO2007028022A2 (en) * | 2005-09-01 | 2007-03-08 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Ｅｒｋインヒビターとしてのピロリジン誘導体 |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| CA2661334C (en) | 2006-08-23 | 2011-11-29 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| JP5363350B2 (ja) * | 2007-03-19 | 2013-12-11 | 武田薬品工業株式会社 | Ｍａｐｋ／ｅｒｋキナーゼ阻害剤 |
| WO2009011904A1 (en) * | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| MX2010005033A (es) | 2007-11-06 | 2010-05-27 | Du Pont | Aminas heterociclicas fungicidas. |
| WO2009146034A2 (en) | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| WO2009156484A2 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| PT2370413E (pt) | 2008-12-08 | 2015-10-23 | Arena Pharm Inc | Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo |
| US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| PE20150666A1 (es) | 2012-03-01 | 2015-05-06 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| CA2882750A1 (en) | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
-
2012
- 2012-02-28 US US14/002,079 patent/US9133187B2/en active Active
- 2012-02-28 ES ES12709429.0T patent/ES2543050T3/es active Active
- 2012-02-28 EP EP20120709429 patent/EP2681215B1/en active Active
- 2012-02-28 MX MX2013009877A patent/MX339873B/es active IP Right Grant
- 2012-02-28 RU RU2013143839/04A patent/RU2013143839A/ru not_active Application Discontinuation
- 2012-02-28 KR KR1020137025269A patent/KR101961500B1/ko not_active Expired - Fee Related
- 2012-02-28 CA CA2828478A patent/CA2828478C/en not_active Expired - Fee Related
- 2012-02-28 WO PCT/US2012/027009 patent/WO2012118850A1/en not_active Ceased
- 2012-02-28 BR BR112013021896A patent/BR112013021896A2/pt not_active Application Discontinuation
- 2012-02-28 CN CN201280020897.3A patent/CN103635472B/zh active Active
- 2012-02-28 JP JP2013556817A patent/JP6085866B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2828478A1 (en) | 2012-09-07 |
| EP2681215A1 (en) | 2014-01-08 |
| MX339873B (es) | 2016-06-15 |
| JP2014506930A (ja) | 2014-03-20 |
| CN103635472A (zh) | 2014-03-12 |
| WO2012118850A1 (en) | 2012-09-07 |
| KR101961500B1 (ko) | 2019-03-22 |
| US9133187B2 (en) | 2015-09-15 |
| EP2681215B1 (en) | 2015-04-22 |
| RU2013143839A (ru) | 2015-04-10 |
| US20130338140A1 (en) | 2013-12-19 |
| CA2828478C (en) | 2019-12-31 |
| KR20140014190A (ko) | 2014-02-05 |
| JP6085866B2 (ja) | 2017-03-01 |
| CN103635472B (zh) | 2018-01-12 |
| BR112013021896A2 (pt) | 2016-11-08 |
| MX2013009877A (es) | 2014-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6085866B2 (ja) | セリン／トレオニンキナーゼインヒビター | |
| AU2022201413B9 (en) | Fused ring compounds | |
| RU2644947C2 (ru) | Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний | |
| JP6716586B2 (ja) | Ｆｇｆｒ４阻害剤としての二環式複素環 | |
| AU2017286380B2 (en) | Azabenzimidazole derivatives as PI3K beta inhibitors | |
| CN103958502B (zh) | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 | |
| US8288381B2 (en) | N-9 substituted purine compounds, compositions and methods of use | |
| US10500212B2 (en) | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | |
| US8828990B2 (en) | N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use | |
| CN104144930A (zh) | 新的中氮茚化合物，它们的制备方法以及包含它们的药物组合物 | |
| US20150031674A1 (en) | Serine/threonine kinase inhibitors | |
| TW201516045A (zh) | 絲胺酸／蘇胺酸激酶抑制劑 | |
| HK1191010A (en) | Serine/threonine kinase inhibitors | |
| HK1191010B (en) | Serine/threonine kinase inhibitors | |
| TW202545531A (zh) | 氮—喹唑啉化合物之使用方法 | |
| BR122024023999A2 (pt) | Compostos e composição farmacêutica | |
| HK1172328B (en) | N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |